CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic diagnostic testing and analysis to routine clinical care, today announced that 12 abstracts highlighting the companys progress in clinical cancer genome sequencing will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 taking place May 31-June 4, 2013 in Chicago.

As clinical adoption of our solid tumor assay, FoundationOne, continues to increase, we are generating a large body of evidence suggesting that a comprehensive genomic profile may provide clinically actionable information for many patients with cancer, said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine. These data include novel findings across many tumor types and for many genomic targets. The 2013 ASCO meeting will be an exciting venue to share and discuss new discoveries in cancer genomics with the broader oncology community.

The schedule for presentations by Foundation Medicine and/or its collaborators is as follows:

Date & Time: Saturday, June 1, 2013 from 8:00 a.m. 12:00 p.m. CT Title: Frequent LOH of CYP2D6 in ER+ breast cancer determined by next-generation sequencing (NGS) Abstract: 534 Session: Poster Discussion Session: Breast Cancer HER2/ER Location: E450b Presenter: Mark J. Ratain, M.D. Research in collaboration with The University of Chicago Comprehensive Cancer Center

Date & Time: Saturday, June 1, 2013 from 8:00 a.m. 12:00 p.m. CT Title: Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions Abstract: 10513 Session: Poster Discussion Session: Sarcoma Location: S102 Presenter: Christine M. Lovly, M.D., Ph.D. Research in collaboration with Vanderbilt-Ingram Cancer Center

Date & Time: Saturday, June 1, 2013 from 1:15 5:00 p.m. CT Title: Next generation sequencing (NGS) in patients with advanced metastatic breast cancer: identification of molecular alterations and analysis of associations with treatment on Phase I studies at MD Anderson Cancer Center Abstract: 1051 Session: General Poster Session: Breast Cancer Triple-Negative/Cytotoxics/Local Therapy Location: S Hall A2 Presenter: Jennifer J. Wheler, M.D. Research in collaboration with MD Anderson Cancer Center

Date & Time: Saturday, June 1, 2013 from 1:15 5:00 p.m. CT Title: Targeted next-generation sequencing of sarcomas for identification of therapeutic targets Abstract: 10577 Session: General Poster Session: Sarcoma Location: S Hall A2 Presenter: Vinod Ravi, M.D. Research in collaboration with MD Anderson Cancer Center

Date & Time: Saturday, June 1, 2013 from 2:00 2:15 p.m. CT Title: Next generation sequencing of genomic and cDNA identifies a high frequency of kinase fusions involving ROS1, ALK, RET, NTRK1, and BRAF in Spitz tumors Abstract: 9002 Session: Oral Abstract Session: Melanoma/Skin Cancers Location: 5406 Presenter: Boris Bastian, M.D., Ph.D., University of California, San Francisco

Date & Time: Sunday, June 2, 2013 from 8:00 8:15 a.m. CT Title: An analysis of ERBB2 alterations (amplifications and mutations) found by next generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients Abstract: 11000 Session: Oral Abstract Session: Tumor Biology Location: E354b Presenter: Massimo Cristofanilli, M.D., F.A.C.P., Thomas Jefferson University-Kimmel Cancer Center

See the original post here:

Foundation Medicine to Present Clinical Data on its FoundationOne™ Cancer Genomic Profile at the 2013 ASCO Annual ...